(Rac) -Reparixin (Standard)

(Rac) -Reparixin (Standard) is the analytical standard of (Rac) -Reparixin. This product is intended for research and analytical applications. (Rac) -Reparixin is the isomer of Reparixin (HY-15251), and can be used as an experimental control. Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.

Product Specifications

CAS Number

[957407-64-6]

UNSPSC

12352100

Target

CXCR; Reference Standards

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Others

Field of Research

Cancer; Endocrinology; Inflammation/Immunology

Smiles

CS(=O)(NC(C(C)C1=CC=C(CC(C)C)C=C1)=O)=O

Molecular Formula

C14H21NO3S

Molecular Weight

283.39

References & Citations

[1]Sousa LF, et al. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics (Sao Paulo) . 2013;68 (3) :391-4.|[2]Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101 (32) :11791-6.|[3]Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016 Apr;75 (4) :721-9.|[4]Crespo J, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol. 2018 Jul 15;201 (2) :814-820.|[5]Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50 (17) :3984-4002.|[6]Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165 (2) :436-54.|[7]Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34 (1) :120-7.